🇺🇸 FOLFOXIRI in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 19

Most-reported reactions

1. Diarrhoea — 4 reports (21.05%)
2. Palmar-Plantar Erythrodysaesthesia Syndrome — 3 reports (15.79%)
3. Nausea — 2 reports (10.53%)
4. Neutropenia — 2 reports (10.53%)
5. Stomatitis — 2 reports (10.53%)
6. Vomiting — 2 reports (10.53%)
7. Agranulocytosis — 1 report (5.26%)
8. Alopecia — 1 report (5.26%)
9. Anaemia — 1 report (5.26%)
10. Arthralgia — 1 report (5.26%)

Source database →

Frequently asked questions

Is FOLFOXIRI approved in United States?

FOLFOXIRI does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for FOLFOXIRI in United States?

Centre Hospitalier Universitaire de Besancon is the originator. The local marketing authorisation holder may differ — check the official source linked above.